OncoCyte Corporation
$2.77
0.42 (18.11%)
0KCC.L Price Chart
| Basic | |
|---|---|
| Market Cap | $53.92M |
| Price | $2.77 |
| 52 Week Range | 0.2082-4.2256 |
| Beta | 0.90 |
| Margins | |
| Gross Profit Margin | 19.14% |
| Operating Profit Margin | -3060.07% |
| Net Profit Margin | -3225.04% |
| Valuation (TTM) | |
| P/E Ratio | -0.84 |
| Price to Sales Ratio | 44.70 |
| Price to Book Ratio | -4.16 |
| PEG Ratio | -3.69 |
Industry
Medical - Pharmaceuticals
Sector
Healthcare
Full-Time Employees
43
Website
IPO Date
2018-01-29T00:00:00.000Z
Description
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
Phone
949 409 7600
Address
15 Cushing, Irvine, CA, 92618, US